Clinical Trial Update: Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating LC002, an experimental therapeutic vaccine, in adults on HAART for HIV infection; safety, tolerability, and immune response assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• LC002

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-10-13